• Home
  1. Home
  2. Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective
Scientific article
OA Policy
English

Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective

ContributorsVon Dach, Elodie; Morel, C M; Murthy, A; Pagani, L; Macedo-Vinas, M; Olearo, Flaminia; Harbarth, Stéphan Juergenorcid
Published inClinical Microbiology and Infection, vol. 23, no. 9, p. 659-666
Publication date2017
Abstract

Few industry-independent studies have been conducted to compare the relative costs and benefits of drugs to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies-linezolid versus trimethoprim-sulfamethoxazole plus rifampicin-for the treatment of MRSA infection.

Affiliation entities
Research groups
Citation (ISO format)
VON DACH, Elodie et al. Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective. In: Clinical Microbiology and Infection, 2017, vol. 23, n° 9, p. 659–666. doi: 10.1016/j.cmi.2017.02.011
Main files (1)
Article (Published version)
accessLevelPublic CC BY-NC-ND
Identifiers
Journal ISSN1198-743X
595views
400downloads

Technical informations

Creation20/10/2017 19:25:00
First validation20/10/2017 19:25:00
Update time08/10/2024 09:13:10
Status update08/10/2024 09:13:10
Last indexation31/10/2024 08:34:32
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack